Then on Thursday, the Department of Commerce reported that building permits rose to 1.02 million in May, their highest level in nearly five years, which bodes well for the housing market. The final positive factor was on Friday, as consumer sentiment rose far above expectations to a six-year high.
Movers and shakers
The biggest mover this past week among the Dogs of the Dow was Johnson & Johnson (NYSE:JNJ), which rose 2.72%. On Monday, the FDA gave priority review status to the company’s hepatitis-C drug, simeprevir. That’s a good sign, as it puts Johnson & Johnson (NYSE:JNJ)’s drug in the lead to be first to market, ahead of Gilead Sciences‘ competing drug sofosbuvir. If you don’t have time to read the company’s annual report, Fool analyst Morgan Housel recently went through it and pointed out five things he learned from reading the annual report.
The article This 10-Stock Dividend Strategy Is Trouncing the Dow originally appeared on Fool.com and is written by Dan Dzombak.
Find Dan Dzombak on Twitter, @DanDzombak, or on his Facebook page, DanDzombak. He has no position in any stocks mentioned. The Motley Fool recommends Intel, Johnson & Johnson, and McDonald’s and owns shares of General Electric, Intel, Johnson & Johnson, and McDonald’s.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.